Vojo Vukovic - 30 Mar 2022 Form 4/A - Amendment Insider Report for AILERON THERAPEUTICS INC (RNTX)

Reporting relationship: Chief Medical Officer
Issuer ticker: RNTX
Reported as of: 30 Mar 2022
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 30 Mar 2022, 20:32:28 UTC
Original report date: 24 Mar 2022
Prior SEC filing: 24 Mar 2022
Next SEC filing: 22 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Richard Wanstall, attorney-in-fact for Vojo Vukovic

Key filing fact

Vojo Vukovic filed Form 4/A - Amendment for AILERON THERAPEUTICS INC (RNTX) on 30 Mar 2022.

Key facts

This page summarizes Vojo Vukovic's Form 4/A - Amendment filing for AILERON THERAPEUTICS INC (RNTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Mar 2022, 20:32.

Change

Previous filing in this sequence was filed on 24 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALRN transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +150,000
Change %
Price: $0.000000
Shares after: 150,000
Date: 30 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $0.4800
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This amendment is being filed to correct the date of grant and the exercise price for the stock option reported on a Form 4 filed by the reporting person on March 24, 2022. This option became effective on March 30, 2022.

Footnote F2

The shares underlying the option are scheduled to vest in equal monthly installments through March 30, 2026.